Brought to you by 
Pieris Pharmaceuticals nets $26.3mm in IPO
29 Jul 2015
Executive Summary
Pieris Pharmaceuticals Inc. netted $26.3mm in its IPO of 10.3mm shares at $2.75 (including partial exercise of the over-allotment option). Pieris is focused on discovering and developing its class of anticalin biotherapeutics for diseases with high unmet medical needs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pieris Pharmaceuticals nets $26.3mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice